India Pharmaceutical Manufacturing Market Size, Share & Trends Analysis Report By Dosage Form, By Manufacturing Type, By Therapeutic Category, And Segment Forecasts, 2024 - 2030

Table of Contents

Chapter 1 Methodology and Scope

• 1.1 Market Segmentation
  • 1.1.1 Market Definitions
  • 1.1.2 Estimates and Forecast Timeline
• 1.2 Objectives
• 1.3 Research Methodology
• 1.4 Information Procurement
  • 1.4.1 Purchased Database
  • 1.4.2 GVR's Internal Database
  • 1.4.3 Secondary Sources
  • 1.4.4 Primary Research
  • 1.4.5 Details of Primary Research
• 1.5 Information or Data Analysis
  • 1.5.1 Data Analysis Models
• 1.6 Market Formulation & Validation
• 1.7 Model Details
  • 1.7.1 Commodity Flow Analysis
    • 1.7.1.1 Approach 1: Commodity Flow Approach
    • 1.7.1.2 Approach 2: Country Wise Market Estimation Using Bottom-up Approach
• 1.8 List of Secondary Sources
• 1.9 List of Abbreviations

Chapter 2 Executive Summary

• 2.1 Market Snapshot
• 2.2 Dosage Form and Manufacturing Type Snapshot
• 2.3 Therapeutic Category Segment Snapshot
• 2.4 Competitive Landscape Snapshot

Chapter 3 Indian Pharmaceutical Manufacturing Market Variables, Trends, and Scope

• 3.1 Market Lineage Outlook
  • 3.1.1 Parent Market Outlook
    • 3.1.1.1 Global Pharmaceutical Market
• 3.2 Market Dynamics
  • 3.2.1 Market Driver Analysis
    • 3.2.1.1 Rising Pharmaceutical R&D Spending
    • 3.2.1.2 Advancements in Pharmaceutical Manufacturing Technologies
    • 3.2.1.3 Rising Geriatric Population and Prevalence of Chronic Disorders
  • 3.2.2 Market Restraint Analysis
    • 3.2.2.1 Challenges in Pharma Supply Chain
    • 3.2.2.2 Inadequate Training and Motivation for Research and Innovations Efforts
• 3.3 Market Analysis Tools
  • 3.3.1 Industry Analysis: Porter's Five Forces
  • 3.3.2 Macroeconomic Analysis
• 3.4 Current & Future Market Opportunity Analysis
  • 3.4.1 Current Opportunity Analysis
    • 3.4.1.1 Increase in Clinical Trials
    • 3.4.1.2 Increasing Investment and Funding in Pharmaceutical IT
  • 3.4.2 The Future of Indian Manufacturing
• 3.5 Queries/Request Raised by CMOs
• 3.6 List of Key 5 Solid Dosage Drugs for Each Therapeutic Area

Chapter 4 India Pharmaceutical Manufacturing Market - Segment Analysis, by Dosage Form, 2018 - 2030 (USD Million)

• 4.1 India Pharmaceutical Manufacturing Market: Dosage Form Movement Analysis
• 4.2 India Pharmaceutical Manufacturing Market Estimates & Forecast, by Dosage Form (USD Million)
• 4.3 Penetration & Growth Prospect Mapping for Dosage Form, 2023
  • 4.3.1 Tablets
    • 4.3.1.1 Tablets Market, 2018 - 2030 (USD Million)
  • 4.3.2 Capsules
    • 4.3.2.1 Capsules Market, 2018 - 2030 (USD Million)
    • 4.3.2.2.1 Soft Gelatin Capsule
    • 4.3.2.2.1.1 Soft Gelatin Capsules Market, 2018 - 2030 (USD Million)
    • 4.3.2.3.1 Hard Gelatin Capsules
    • 4.3.1.3.1.1 Hard Gelatin Capsules Market, 2018 - 2030 (USD Million)
    • 4.3.2.4.1 Others
    • 4.3.2.4.1.1 Others Market, 2018 - 2030 (USD Million)
  • 4.3.3 Injectables
    • 4.3.3.1 Injectables Market, 2018 - 2030 (USD Million)
  • 4.3.4 Others
    • 4.3.4.1 Others Market, 2018 - 2030 (USD Million)

Chapter 5 India Pharmaceutical Manufacturing Market - Segment Analysis, by Manufacturing Type, 2018 - 2030 (USD Million)

• 5.1 India Pharmaceutical Manufacturing Market: Manufacturing Type Movement Analysis
• 5.2 India Pharmaceutical Manufacturing Market Estimates & Forecast, by Manufacturing Type (USD Million)
• 5.3 Penetration & Growth Prospect Mapping for Manufacturing Type, 2023
  • 5.3.1 IN-HOUSE MANUFACTURING
    • 5.3.1.1 In-house MAnufacturing Market, 2018 - 2030 (USD Million)
  • 5.3.2 CONTRACT MANUFACTURING
    • 5.3.2.1 Contract Manufacturing Market, 2018 - 2030 (USD Million)

Chapter 6 India Pharmaceutical Manufacturing Market - Segment Analysis, by Therapeutic Category, 2018 - 2030 (USD Million)

• 6.1 India Pharmaceutical Manufacturing Market: Therapeutic Category Movement Analysis
• 6.2 India Pharmaceutical Manufacturing Market Estimates & Forecast, by Therapeutic Category (USD Million)
• 6.3 Penetration & Growth Prospect Mapping for Therapeutic Category, 2023
• 6.4 Endocrinology
  • 6.4.1 Canagliflozin
    • 6.4.1.1 Approval
    • 6.4.1.2 Patent Expiry
    • 6.4.1.3 Available Combinations
    • 6.4.1.4 Countries The Drug is Available in
    • 6.4.1.5 Trends
  • 6.4.2 Empagliflozin
    • 6.4.2.1 Approval
    • 6.4.2.2 Patent Expiry
    • 6.4.2.3 Available Combinations
    • 6.4.2.4 Countries Drug Available in
    • 6.4.2.5 Trends
  • 6.4.3 Semaglutide
    • 6.4.3.1 Approval
    • 6.4.3.2 Patent Expiry
    • 6.4.3.3 Available Combinations
    • 6.4.3.4 Countries Drug Available in
    • 6.4.3.5 Trends
  • 6.4.4 Tirzepatide
    • 6.4.4.1 Approval
    • 6.4.4.2 Patent Expiry
    • 6.4.4.3 Available Combinations
    • 6.4.4.4 Countries Drug Available in
    • 6.4.4.5 Trends
  • 6.4.5 Linagliptin
    • 6.4.5.1 Approval
    • 6.4.5.2 Patent Expiry
    • 6.4.5.3 Available Combinations
    • 6.4.5.4 Countries Drug Available in
    • 6.4.5.5 Trends
  • 6.4.6 Alogliptin
    • 6.4.6.1 Approval
    • 6.4.6.2 Patent Expiry
    • 6.4.6.3 Available Combinations
  • 6.4.7 Trelagliptin
  • 6.4.8 Myo-Inositol
• 6.5 Cardiovascular
  • 6.5.1 Treprostinil
    • 6.5.1.1 Approval
    • 6.5.1.2 Patent Expiry
    • 6.5.1.3 Available Combinations
    • 6.5.1.4 Trends
  • 6.5.2 Azilsartan
    • 6.5.2.1 Approval
    • 6.5.2.2 Patent Expiry
    • 6.5.2.3 Available Combinations
  • 6.5.3 Azilsartan+Amlodipine
  • 6.5.4 Amlodipine + Lisinopril
  • 6.5.5 Sparsentan
    • 6.5.5.1 Approval
    • 6.5.5.2 Patent Expiry
    • 6.5.5.3 Available Combinations
  • 6.5.6 Esaxerenone
    • 6.5.6.1 Approval
    • 6.5.6.2 Available Combinations
• 6.6 CNS
  • 6.6.1 Cariprazine
    • 6.6.1.1 Approval
    • 6.6.1.2 Patent Expiry
    • 6.6.1.3 Available Combinations
    • 6.6.1.4 Countries Drug Available in
    • 6.6.1.5 Trends
  • 6.6.2 Brexpiprazole
    • 6.6.2.1 Approval
    • 6.6.2.2 Patent Expiry
    • 6.6.2.3 Available Combinations
    • 6.6.2.4 Trends
  • 6.6.3 Lisdexamfetamine
    • 6.6.3.1 Approval
    • 6.6.3.2 Patent Expiry
    • 6.6.3.3 Available Combinations
    • 6.6.3.4 Trends
  • 6.6.4 Vortioxetine
    • 6.6.4.1 Approval
    • 6.6.4.2 Patent Expiry
    • 6.6.4.3 Available Combinations
    • 6.6.4.4 Countries Drug Available in
    • 6.6.4.5 Trends
  • 6.6.5 Mirogabalin Besylate
  • 6.6.6 Lasmiditan
    • 6.6.6.1 Approval
    • 6.6.6.2 Patent Expiry
    • 6.6.6.3 Available Combinations
    • 6.6.6.4 Trends
  • 6.6.7 Siponimod
    • 6.6.7.1 Approval
    • 6.6.7.2 Patent Expiry
    • 6.6.7.3 Available Combinations
    • 6.6.7.4 Trends
• 6.7 Analgesics
  • 6.7.1 Ibuprofen+Famotidine
  • 6.7.2 Upadacitinib
    • 6.7.2.1 Approval
    • 6.7.2.2 Patent Expiry
    • 6.7.2.3 Available Combinations
    • 6.7.2.4 Countries Drug Available in
    • 6.7.2.5 Trends
• 6.8 Antacid
  • 6.8.1 Pantoprazole Gastro Resistant
    • 6.8.1.1 Approval
    • 6.8.1.2 Patent Expiry
• 6.9 Antibiotic
  • 6.9.1 Doxycycline
    • 6.9.1.1 Approval
    • 6.9.1.2 Patent Expiry
    • 6.9.1.3 Available Combinations
  • 6.9.2 Tedizolid
• 6.10 Antifungal
  • 6.10.1 Posaconazole
    • 6.10.1.1 Approval
    • 6.10.1.2 Patent Expiry
    • 6.10.1.3 Available Combinations
• 6.11 Antiprotozoal
  • 6.11.1 Nitazoxanide
    • 6.11.1.1 Approval
    • 6.11.1.2 Patent Expiry
    • 6.11.1.3 Available Combinations
• 6.12 Hematology
  • 6.12.1 Lenalidomide
    • 6.12.1.1 Approval
    • 6.12.1.2 Patent Expiry
    • 6.12.1.3 Available Combinations
    • 6.12.1.4 Trends
  • 6.12.2 Daprodustat
    • 6.12.2.1 Approval
    • 6.12.2.2 Patent Expiry
    • 6.12.2.3 Available Combinations
    • 6.12.2.4 Trends
  • 6.12.3 Roxadustat
    • 6.12.3.1 Approval
    • 6.12.3.2 Available Combinations
    • 6.12.3.3 Countries Drug Available in
  • 6.12.4 Edoxaban
    • 6.12.4.1 Approval
    • 6.12.4.2 Patent Expiry
    • 6.12.4.3 Available Combinations
    • 6.12.4.4 Countries Drug Available in
    • 6.12.4.5 Trends
  • 6.12.5 Avatrombopag
    • 6.12.5.1 Approval
    • 6.12.5.2 Available Combinations
    • 6.12.5.3 Trends
• 6.13 Others
  • 6.13.1 Linaclotide
    • 6.13.1.1 Approval
    • 6.13.1.2 Patent Expiry
    • 6.13.1.3 Available Combinations
    • 6.13.1.4 Trends
  • 6.13.2 Apremilast
    • 6.13.2.1 Approval
    • 6.13.2.2 Patent Expiry
    • 6.13.2.3 Available Combinations
    • 6.13.2.4 Trends
  • 6.13.3 Tegoprazan
  • 6.13.4 Suvorexant
    • 6.13.4.1 Approval
    • 6.13.4.2 Patent Expiry
    • 6.13.4.3 Available Combinations
    • 6.13.4.4 Trends
  • 6.13.5 Vonoprazan
    • 6.13.5.1 Approval
    • 6.13.5.2 Patent Expiry
    • 6.13.5.3 Available Combinations
    • 6.13.5.4 Trends
  • 6.13.6 Rolapitant
    • 6.13.6.1 Approval
    • 6.13.6.2 Patent Expiry
    • 6.13.6.3 Available Combinations
  • 6.13.7 Elagolix
    • 6.13.7.1 Approval
    • 6.13.7.2 Patent Expiry
    • 6.13.7.3 Available Combinations
    • 6.13.7.4 Trends

Chapter 7 Global Oncology Pharmaceutical Manufacturing Market

• 7.1 List of Cancer Molecules Going Off Patent Between 2023 and 2030
• 7.2 Global Overview
• 7.3 Market Opportunities, By Type of Cancer

Chapter 8 India Injectables Pharmaceutical Manufacturing Market

• 8.1 Complete India Market Overview
• 8.2 Exports in Injectable Formulation
  • 8.2.1 By Therapeutic Category
    • 8.2.1.1 Endocrinology
    • 8.2.1.2 Cardiovascular
    • 8.2.1.3 CNS
    • 8.2.1.4 Analgesics
    • 8.2.1.5 Antacid
    • 8.2.1.6 Antibiotic
    • 8.2.1.7 Antifungal
    • 8.2.1.8 Antiprotozoal
    • 8.2.1.9 Hematology
    • 8.2.1.10 Others
  • 8.2.2 By Dosage Form
    • 8.2.2.1 Intravenous
    • 8.2.2.2 Subcutaneous
    • 8.2.2.3 Intramuscular
    • 8.2.2.4 Others

Chapter 9 Competitive Landscape

• 9.1 Participants' Overview
• 9.2 Financial Performance
• 9.3 Public Players Financial Overview
  • 9.3.1 Alkem Laboratories Ltd.
    • 9.3.1.1 Alkem's Performance in Key Therapeutic Segments
    • 9.3.1.2 Performance of Alkem's Top 10 Brands
  • 9.3.2 Sun Pharmaceutical Industries Ltd.
    • 9.3.2.1 India Business Therapeutic Revenue Break-Up
    • 9.3.2.2 Business-Wise Revenue Share
  • 9.3.3 Ajanta Pharma Ltd.
    • 9.3.3.1 Focused Presence in Key Therapy Areas
  • 9.3.4 Cipla Inc.
    • 9.3.4.1 Manufacturing capabilities highlights (in million units) FY 2022-23
    • 9.3.4.2 Global Presence
    • 9.3.4.3 Branded Prescription Business
    • 9.3.4.4 API Manufacturing Capability
  • 9.3.5 Eris Lifesciences
    • 9.3.5.1 Eris Lifesciences Performance in Key Therapeutic Segments
  • 9.3.6 Lupin
    • 9.3.6.1 Lupin's Therapy-Wise Ranking
  • 9.3.7 Glenmark Pharmaceuticals Ltd.
    • 9.3.7.1 Revenue Distribution by Geographies
    • 9.3.7.2 Top Brands of Glenmark in Top 300 of IPM
  • 9.3.8 Torrent Pharmaceuticals Ltd.
    • 9.3.8.1 Revenue Distribution by Geographies
• 9.4 Participant Categorization
  • 9.4.1 Key Company Market Share Analysis
  • 9.4.2 Strategy Mapping
    • 9.4.2.1 Acquisition
    • 9.4.2.2 Partnership & Collaborations
    • 9.4.2.3 Product Launches
    • 9.4.2.4 Expansion
    • 9.4.2.5 Others (Investment, Divestment, Market Penetration, Funding, & Approval)
• 9.5 List of Key CMOs

Chapter 10 Conclusion

List of Tables

• Table 1 List of abbreviation
• Table 2 List of data points generally requested by the Indian CMOs from Grand View Research Inc.
• Table 3 India pharmaceutical manufacturing market revenue estimates and forecast, by dosage form, 2018 - 2030 (USD Million)
• Table 4 India pharmaceutical manufacturing market revenue estimates and forecast, by manufacturing type, 2018 - 2030 (USD Million)
• Table 5 India pharmaceutical manufacturing market revenue estimates and forecast, by therapeutic category, 2018 - 2030 (USD Million)
• Table 6 Patent expiry data for approved formulation:
• Table 7 Brand name/prescription products:
• Table 8 Combinations products:
• Table 9 Patent expiry data for approved formulation:
• Table 10 Brand name/prescription products:
• Table 11 Combinations products:
• Table 12 Patent expiry data for approved formulation:
• Table 13 Brand name/prescription products:
• Table 14 Patent expiry data for approved formulation:
• Table 15 Brand name/prescription products:
• Table 16 Patent expiry data for approved formulation:
• Table 17 Brand name/prescription products:
• Table 18 Combinations products:
• Table 19 Patent expiry data for approved formulation:
• Table 20 Brand name/prescription products:
• Table 21 Generic products:
• Table 22 Combinations products:
• Table 23 Patent expiry data for approved formulation:
• Table 24 Brand name/prescription products:
• Table 25 Generic products:
• Table 26 Combination Products:
• Table 27 Patent expiry data for approved formulation:
• Table 28 Brand name/prescription products:
• Table 29 Combinations products:
• Table 30 Patent expiry data for approved formulation:
• Table 31 Brand name/prescription products:
• Table 32 Brand name/prescription products:
• Table 33 Patent expiry data for approved formulation:
• Table 34 Brand name/prescription products:
• Table 35 Combinations products:
• Table 36 Patent expiry data for approved formulation:
• Table 37 Brand name/prescription products:
• Table 38 Generic products:
• Table 39 Combinations products:
• Table 40 Patent expiry data for approved formulation:
• Table 41 Brand name/prescription products:
• Table 42 Generic products:
• Table 43 Patent expiry data for approved formulation:
• Table 44 Brand name/prescription products:
• Table 45 Patent expiry data for approved formulation:
• Table 46 Brand name/prescription products:
• Table 47 Patent expiry data for approved formulation:
• Table 48 Brand name/prescription products:
• Table 49 Patent expiry data for approved formulation:
• Table 50 Brand name/prescription products:
• Table 51 Patent expiry data for approved formulation:
• Table 52 Patent expiry data for approved formulation:
• Table 53 Brand name/prescription products:
• Table 54 Unapproved products:
• Table 55 Patent expiry data for approved formulation:
• Table 56 Brand name/prescription products:
• Table 57 Generic products:
• Table 58 Patent expiry data for approved formulation:
• Table 59 Brand name/prescription products:
• Table 60 Generic Products:
• Table 61 Patent expiry data for approved formulation:
• Table 62 Brand name/prescription products:
• Table 63 Generic products:
• Table 64 Patent expiry data for approved formulation:
• Table 65 Brand name/prescription products:
• Table 66 Brand name/prescription products:
• Table 67 Patent expiry data for approved formulation:
• Table 68 Brand name/prescription products:
• Table 69 Brand name/prescription products:
• Table 70 Patent expiry data for approved formulation:
• Table 71 Brand name/prescription products:
• Table 72 Patent expiry data for approved formulation:
• Table 73 Brand name/prescription products:
• Table 74 Generic Products:
• Table 75 Combinations products:
• Table 76 Patent expiry data for approved formulation:
• Table 77 Brand name/prescription products:
• Table 78 Patent expiry data for approved formulation:
• Table 79 Combinations products:
• Table 80 Patent expiry data for approved formulation:
• Table 81 Brand name/prescription products:
• Table 82 Patent expiry data for approved formulation:
• Table 83 Brand name/prescription products:
• Table 84 Combinations products:
• Table 85 Opportunities for Generic Manufacturers
• Table 86 Opportunities for Branded Manufacturers

List of Figures

• Fig. 1 India pharmaceutical manufacturing market segmentation
• Fig. 2 Market research process
• Fig. 3 Data triangulation techniques
• Fig. 4 Primary research pattern
• Fig. 5 Market research approaches
• Fig. 6 Value chain based sizing & forecasting
• Fig. 7 QFD modelling for market share assessment
• Fig. 8 Market formulation & validation
• Fig. 9 Market snapshot
• Fig. 10 Dosage form and manufacturing type segment snapshot
• Fig. 11 Therapeutic category segment snapshot
• Fig. 12 Competitive landscape snapshot
• Fig. 13 Pharmaceuticals market value, 2023 (USD Million)
• Fig. 14 Market dynamics
• Fig. 15 India product flow
• Fig. 16 Porter's Five Forces analysis
• Fig. 17 PESTLE analysis
• Fig. 18 India pharmaceutical manufacturing market: Product outlook and key takeaways
• Fig. 19 India pharmaceutical manufacturing market: Dosage form movement analysis
• Fig. 20 Penetration & growth prospect mapping for dosage form, 2023
• Fig. 21 Tablets market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 22 Capsules market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 23 Soft gelatin capsule market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 24 Hard gelatin capsules market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 25 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 26 Injectables market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 27 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 28 India pharmaceutical manufacturing market: Manufacturing type outlook and key takeaways
• Fig. 29 India pharmaceutical manufacturing market: Manufacturing type movement analysis
• Fig. 30 Penetration & growth prospect mapping for manufacturing type, 2023
• Fig. 31 In-house manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 32 Advantages of in-house CRO & CMO
• Fig. 33 Contract manufacturing market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 34 Contract manufacturing activities
• Fig. 35 India pharmaceutical manufacturing market: Therapeutic category outlook and key takeaways
• Fig. 36 India pharmaceutical manufacturing market: Therapeutic category movement analysis
• Fig. 37 Penetration & growth prospect mapping for therapeutic category, 2023
• Fig. 38 Endocrinology market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 39 Canagliflozin market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 40 Empagliflozin market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 41 Semaglutide market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 42 Tirzepatide market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 43 Linagliptin market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 44 Alogliptin market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 45 Trelagliptin market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 46 Myo-inositol market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 47 Cardiovascular market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 48 Treprostinil market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 49 Azilsartan medoxomil market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 50 Azilsartan+Amlodipine market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 51 Amlodipine + Lisinopril market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 52 Sparsentan market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 53 Esaxerenone market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 54 CNS market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 55 Cariprazine market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 56 Brexpiprazole market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 57 Lisdexamfetamine market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 58 Vortioxetine market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 59 Mirogabalin besylate market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 60 Lasmiditan market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 61 Siponimod market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 62 Analgesics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 63 Ibuprofen+Famotidine market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 64 Upadacitinib market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 65 Antacid market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 66 Pantoprazole market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 67 Antibiotic market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 68 Doxycycline market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 69 Tedizolid market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 70 Antifungal market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 71 Posaconazole market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 72 Antiprotozoal market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 73 Nitazoxanide market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 74 Hematology market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 75 Lenalidomide market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 76 Daprodustat market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 77 Roxadustat market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 78 Edoxaban market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 79 Avatrombopag market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 80 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 81 Linaclotidemarket estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 82 Apremilast market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 83 Tegoprazan market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 84 Suvorexant market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 85 Vonoprazan market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 86 Rolapitant market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 87 Elagolix market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 88 Global oncology market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 89 Oncology opportunities
• Fig. 90 India injectable market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 91 Endocrinology market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 92 Cardiovascular market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 93 CNS market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 94 Analgesics market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 95 Antacid market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 96 Antibiotic market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 97 Antifungal market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 98 Antiprotozoal market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 99 Hematology market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 100 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 101 Intravenous market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 102 Subcutaneous market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 103 Intramuscular market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 104 Others market estimates and forecast, 2018 - 2030 (USD Million)
• Fig. 105 Company/competition categorization
• Fig. 106 Key company market share analysis, 2023
• Fig. 107 Strategy mapping